Synergy Pharma (SGYP) Files IND for SP-333
Get Alerts SGYP Hot Sheet
Join SI Premium – FREE
Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) announced that an Investigational New Drug (IND) application was submitted on September 7, 2012 for clinical evaluation of SP-333 to treat inflammatory bowel disease (IBD). SP-333 is a second-generation guanylate cyclase-C (GC-C) agonist with the potential to treat GI disorders and diseases.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Johnson & Johnson's (JNJ) Janssen Receives FDA Approval for Edurant
- FreightCar America (RAIL) Announces CEO Transition
- Arvinas (ARVN) Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!